Literature DB >> 28570088

Viral hepatitis B, active component, U.S. Armed Forces, 2007-2016.

Shauna Stahlman, Valerie F Williams, Alexis A Oetting.   

Abstract

During 2007-2016, there were 1,258 and 1,259 incident diagnoses of acute and chronic hepatitis B virus (HBV) infection, respectively. The overall incidence rates of diagnoses of acute and chronic hepatitis B were both 10.0 per 100,000 person-years (p-yrs). Overall crude incidence rates of acute hepatitis B were highest among females, Navy members, Asian/Pacific Islander and non-Hispanic black service members, those in healthcare occupations, recruits, and service members with no history of deployment. Overall incidence rates of chronic hepatitis B were highest among service members who were female; in the Navy or the Army; in healthcare occupations; and of non-recruit status. Asian/Pacific Islander service members, those of other/unknown race/ethnicity, and non-Hispanic black service members had overall rates of chronic hepatitis B that were more than 41, 11, and 10 times that of non-Hispanic white service members, respectively. Crude annual incidence rates of acute hepatitis B fluctuated between 7.7 per 100,000 p-yrs and 13.2 per 100,000 p-yrs during the surveillance period. Approximately one of 10 acute cases and close to one of five chronic cases had at least one HBV-related hospitalization. Rates of hospitalized cases of acute hepatitis B decreased over the 10-year period.

Entities:  

Mesh:

Year:  2017        PMID: 28570088

Source DB:  PubMed          Journal:  MSMR        ISSN: 2152-8217


  1 in total

1.  Hepatitis B seroprevalence in the U.S. military and its impact on potential screening strategies.

Authors:  Paul T Scott; Robert L Cohen; David M Brett-Major; Shilpa Hakre; Jennifer A Malia; Jason F Okulicz; Charmagne G Beckett; Jason M Blaylock; Michael A Forgione; Stephen A Harrison; Clinton K Murray; Francisco J Rentas; Roland L Fahie; Adam W Armstrong; Aatif M Hayat; Laura A Pacha; Peter Dawson; Beth Blackwell; Angelia A Eick-Cost; Hala H Maktabi; Nelson L Michael; Linda L Jagodzinski; Steven B Cersovsky; Sheila A Peel
Journal:  Mil Med       Date:  2020-09-18       Impact factor: 1.437

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.